ストックスクリーナーアプリを入手
5.465
17.10%
-1.145
Zentalis Pharmaceuticals Inc (ZNTL) 最新ニュース
Zentalis Pharmaceuticals (ZNTL) price target increased by 19.05% to 5.83 - MSN
A Look At Zentalis Pharmaceuticals (ZNTL) Valuation After Azenosertib Dose Selection Milestone - Yahoo Finance
Guggenheim Increases Zentalis Price Target, Sparking Investor Interest - timothysykes.com
Zentalis Stock Jumps as Guggenheim Lifts Price Target on Cancer Program Success - StocksToTrade
Zentalis Pharmaceuticals: Price Target Boost Sparks Speculative Momentum - timothysykes.com
Zentalis Surges 20% on WEE1 Inhibitor Dose Selection—But Is Aprea the Real Winner in This Space? - Barchart.com
Jefferies raises Zentalis stock price target on ovarian cancer trial data - Investing.com Canada
What's behind the surge in Zentalis stock? - MSN
What's Behind The Surge In Zentalis Stock? - Benzinga
Today's Analyst Rating Update for ZNTL: Buy Rating Maintained wi - GuruFocus
H.C. Wainwright reiterates Zentalis stock rating on pivotal dose selection By Investing.com - Investing.com Canada
Azenosertib Shows Promising Results in Cyclin E1-Positive Platinum-Resistant Ovarian Cancer: Zentalis Advances Registration-Intent Trials - Minichart
Zentalis Pharmaceuticals Announces 400mg QD 5:2 Azenosertib Monotherapy as the Pivotal Study Dose in Cyclin E1-Positive Platinum-Resistant Ovarian Cancer - Bitget
Zentalis Advances Azenosertib Dose in DENALI Phase 2 - TipRanks
Zentalis Selects 400mg QD 5:2 Azenosertib Dose for Pivotal Ovarian Cancer Study - National Today
Zentalis selects 400mg QD 5:2 as pivotal azenosertib dose; DENALI topline due YE2026 - TradingView — Track All Markets
Azenosertib 400mg dose to anchor Zentalis (NASDAQ: ZNTL) late-stage ovarian cancer trials - Stock Titan
Ovarian cancer drug moves toward pivotal trials with 400mg dose - Stock Titan
ZNTL Should I Buy - Intellectia AI
Zentalis Pharmaceuticals PAO sells $7.8k in stock - Investing.com
Zentalis Pharmaceuticals announces inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView — Track All Markets
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Two new Zentalis hires get stock options priced at $2.57 - Stock Titan
ZNTL PE Ratio & Valuation, Is ZNTL Overvalued - Intellectia AI
Here's What to Expect From West Pharmaceutical's Next Earnings Report - Barchart.com
Sentiment Review: Is Zentalis Pharmaceuticals Inc currently under institutional pressure2026 Analyst Calls & Community Consensus Trade Alerts - baoquankhu1.vn
Brokers Issue Forecasts for ZNTL FY2030 Earnings - MarketBeat
Guggenheim Reiterates Buy Rating for Zentalis Pharmaceuticals (NASDAQ:ZNTL) - Defense World
Zentalis Pharmaceuticals (NASDAQ:ZNTL) Downgraded by Wall Street Zen to "Sell" - MarketBeat
TD Cowen reiterates Zentalis Pharmaceuticals stock Buy rating By Investing.com - Investing.com Canada
TD Cowen reiterates Zentalis Pharmaceuticals stock Buy rating - Investing.com
Zentalis Pharmaceuticals' (ZNTL) "Buy" Rating Reiterated at Guggenheim - MarketBeat
Oppenheimer reiterates Zentalis stock rating on ovarian cancer drug By Investing.com - Investing.com Canada
H.C. Wainwright reiterates Zentalis stock rating, $10 target By Investing.com - Investing.com Canada
Can Zentalis Pharmaceuticals Inc expand its profit marginsWeekly Market Outlook & Real-Time Sentiment Analysis - baoquankhu1.vn
H.C. Wainwright Maintains Zentalis Pharmaceuticals(ZNTL.US) With Buy Rating, Maintains Target Price $10 - Moomoo
Zentalis Pharmaceuticals 2025 Annual Report: Azenosertib Development, Strategic Restructuring, and Competitive Positioning - Minichart
Zentalis Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Zentalis (ZNTL) centers strategy on azenosertib for Cyclin E1-positive ovarian cancer - Stock Titan
Zentalis Pharmaceuticals 10-K: $0 Revenue, $(137.1)M Net Loss - TradingView
Zentalis Pharmaceuticals (NASDAQ:ZNTL) Posts Earnings Results - MarketBeat
Zentalis Pharmaceuticals Reports Full Year 2025 Financial Results and Operational Updates - Bitget
Zentalis Pharmaceuticals (Nasdaq: ZNTL) cuts costs, extends cash runway into 2027 - Stock Titan
Zentalis Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Investment Recap: Can Zentalis Pharmaceuticals Inc expand its profit margins2026 Reactions & Weekly High Potential Alerts - baoquankhu1.vn
ZNTL SEC FilingsZentalis Pharmaceuticals, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Aug Intraday: Can Zentalis Pharmaceuticals Inc keep up with sector leaders2026 Analyst Calls & Fast Gaining Stock Strategy Reports - baoquankhu1.vn
Profit Recap: Does Zentalis Pharmaceuticals Inc have a sustainable dividendEarnings Beat & Consistent Income Trade Ideas - baoquankhu1.vn
Zentalis Pharmaceuticals Inc expected to post a loss of 58 cents a shareEarnings Preview - TradingView
ZNTL Stock Price, Quote & Chart | ZENTALIS PHARMACEUTICALS INC (NASDAQ:ZNTL) - ChartMill
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Given Consensus Rating of "Hold" by Brokerages - MarketBeat
Zentalis Pharmaceuticals (NASDAQ:ZNTL) Now Covered by Analysts at Wells Fargo & Company - Defense World
Zentalis Pharmaceuticals (ZNTL) to Release Earnings on Wednesday - MarketBeat
Zentalis Pharmaceuticals to Present Two Posters at the American Association for Cancer Research (AACR) Annual Meeting 2026 - Bitget
Zentalis Pharmaceuticals to Present Two Posters at the - GlobeNewswire
Tech Rally: Can Zentalis Pharmaceuticals Inc expand its profit margins - baoquankhu1.vn
Wells Fargo & Company Initiates Coverage on Zentalis Pharmaceuticals (NASDAQ:ZNTL) - MarketBeat
0.62%
大文字化:
|
ボリューム (24 時間):